Terkko Navigator / BioDrugs

Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies

Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology

The Path Towards a Tailored Clinical Biosimilar Development

Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferio

The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma

Correction to: In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies

Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure

MYL1501D Insulin Glargine: A Review in Diabetes Mellitus

Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis

Cell-Free Protein Synthesis: A Promising Option for Future Drug Development

Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies

Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status

In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies

Anti-HIV-1 Antibodies: An Update

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Stu

Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial

Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin® with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology

Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Stu

Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Doubl

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars

Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria

Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date

A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera® ) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!

Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study

Acknowledgement to Referees

Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

Prediction of Immunogenicity of Therapeutic Proteins: Validity of Computational Tools

Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor: Current Status and Future Challenges in Cancer Therapy

Therapeutic Potential of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibitors in Polycystic Kidney Disease

Application of Glatiramer Acetate to Neurodegenerative Diseases beyond Multiple Sclerosis: The Need for Disease-Specific Approaches

Understanding and Applying Regulatory Guidance on the Nonclinical Development of Biotechnology-Derived Pharmaceuticals

Fibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases

Selective Targeting of Cancer Stem Cells: A New Concept in Cancer Therapeutics

RNAi Therapy for HIV Infection: Principles and Practicalities

Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil): Profile Report